QuatRx Pharmaceuticals Withdraws Registration Statement For Initial Public Offering
Posted on: Monday, 10 July 2006, 18:00 CDT
ANN ARBOR, Mich., July 10 /PRNewswire/ -- QuatRx Pharmaceuticals Company announced today that it has withdrawn its initial public offering and its S-1 registration statement filed with the Securities and Exchange Commission (SEC) due to market conditions.
About QuatRx
QuatRx is a pharmaceutical company focused on discovering, licensing, developing and commercializing compounds in the endocrine, metabolic and cardiovascular therapeutic areas. QuatRx, founded in 2000, is headquartered in Ann Arbor, Michigan and has operations in Europe through Hormos Medical Ltd., a wholly-owned subsidiary located in Turku, Finland.
QuatRx Pharmaceuticals Company
CONTACT: Gary Onn of QuatRx Pharmaceuticals Company, +1-734-913-9900x119
Web site: http://www.quatrx.com/
Source: PRNewswire
Related Articles
- Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy
- QuatRx Pharmaceuticals Announces Presentation of Further Data From Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
- QuatRx Pharmaceuticals to Present at 26th Annual JP Morgan Healthcare Conference
- QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (Ospemifene) to Treat Postmenopausal Vaginal Syndrome
- QuatRx Pharmaceuticals Reports Positive Results From a Phase 2 Trial of Fispemifene
- QuatRx Pharmaceuticals Announces New Management Appointments
- QuatRx Pharmaceuticals to Expand Portfolio of Products in Women's Health Through Development Program for HSD Inhibitors
- QuatRx Pharmaceuticals Advances U.S. Clinical Trials for Fispemifene and Ospemifene; Richard Fox Joins Board Of Directors
- QuatRx Pharmaceuticals Licenses Novel Lipid-Lowering Drug
 |
 |
User Comments (0)
RSS Feeds